GetTopicDetailResponse(id=a13516191d8, topicName=Sezary綜合征, introduction=Sezary綜合征, content=null, image=null, comments=3, allHits=1002, url=https://h5.medsci.cn/topic?id=16191, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=93965, tagList=[TagDto(tagId=93965, tagName=Sezary綜合征)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1581021, encodeId=2a6615810218a, content=<a href='/topic/show?id=a13516191d8' target=_blank style='color:#2F92EE;'>#Sezary綜合征#</a>, objectTitle=Lancet Haemat：瘤內(nèi)注射TTI-621治療復(fù)發(fā)性或難治性蕈樣真菌病或Sézary綜合征的安全性, objectType=article, longId=218260, objectId=769721826066, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=769721826066, replyNumber=0, likeNumber=88, createdTime=2021-10-10, rootId=0, userName=ms9608593228839890, userId=336016689281, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=769721826066, moduleTitle=Lancet Haemat：瘤內(nèi)注射TTI-621治療復(fù)發(fā)性或難治性蕈樣真菌病或Sézary綜合征的安全性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=769721826066)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581020, encodeId=ef0715810203b, content=<a href='/topic/show?id=a13516191d8' target=_blank style='color:#2F92EE;'>#Sezary綜合征#</a>, objectTitle=JEADV：根據(jù)基線血液腫瘤負(fù)荷評(píng)估Mogamulizumab在蕈樣真菌病或Sézary綜合征中的療效, objectType=article, longId=214719, objectId=322a214e19fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=322a214e19fe, replyNumber=0, likeNumber=79, createdTime=2021-07-25, rootId=0, userName=ms9608593228839890, userId=336016689281, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=322a214e19fe, moduleTitle=JEADV：根據(jù)基線血液腫瘤負(fù)荷評(píng)估Mogamulizumab在蕈樣真菌病或Sézary綜合征中的療效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=322a214e19fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581019, encodeId=701e158101960, content=<a href='/topic/show?id=a13516191d8' target=_blank style='color:#2F92EE;'>#Sezary綜合征#</a>, objectTitle=Blood：體外光化學(xué)療法(ECP)可明顯改善Sezary綜合征和真菌紅皮病患者預(yù)后, objectType=article, longId=178701, objectId=9cce1e8701ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9cce1e8701ce, replyNumber=0, likeNumber=91, createdTime=2019-09-04, rootId=0, userName=ms9608593228839890, userId=336016689281, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9cce1e8701ce, moduleTitle=Blood：體外光化學(xué)療法(ECP)可明顯改善Sezary綜合征和真菌紅皮病患者預(yù)后, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=9cce1e8701ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
